1/18 Fig. 1a





Fig. 1b



2/18 Fig. 2






Fig. 3




**BEST AVAILABLE COPY** 


3/18 Fig. 4




Effector: Target ratio


4/18 Fig. 5







5/18 Fig. 6






6/18 Fig. 7






7/18 Fig. 8





BEST AVAILABLE COPY

8/18 Fig. 9



9/17 Fig. 10





Days after Her-2/CT26 transfer

10/18 Fig. 11






Fig. 12a




11/18 Fig. 12b

Her2-CT26



**CT26** 



12/18 Fig. 13a





Fig. 13b



13/18 Fig. 13c





Fig. 13d



14/18 Fig. 14a






Fig. 14b




15/18 Fig. 14c



Days after tumor challagne

Fig. 15a



16/18 Fig. 15b






Fig. 15c




PCT/KR2003/001400

17/18 Fig. 15d



Days after Her2-CT26 transfer



Days after Her2-CT26 transfer

18/18 Fig. 16

